Browse News
Filter News
Found 2,041 articles
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
Therapyte delivers keynote on real case-study developing digital innovations with Real-World Data in Prostate Cancer at the European RWD Summit 2024.
4/17/2024
Berlin, 8th of April, 2024 - Konstantinos Mouratis, CEO of Therapyte, spoke at the European RWD Summit held by Honic at the GovTech Campus in Berlin, Germany.
-
Independent Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis, Including in Polytrauma Patients
4/17/2024
Immunexpress, Pty Ltd. today announced the presentation of two posters evaluating SeptiCyte® RAPID at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 2024, to take place from April 27 – 30 in Barcelona, Spain.
-
Oncology Market Size to Exceed USD 521.60 Billion by 2033 | CAGR 8.9%
4/16/2024
The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024
-
Biologics Contract Development Market Size to Hit USD 18.68 Bn by 2033 | CAGR 8.2%
4/15/2024
According to Nova One Advisor, the global biologics contract development market size was accounted for USD 8.49 billion in 2023 and it is increasing around USD 18.68 billion by 2033 with a CAGR of 8.2% from 2024 to 2033.
-
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
4/15/2024
BC Platforms, a global leader in real world data, healthcare data management, and analytics, announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine.
-
UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
4/12/2024
Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
-
Clinical Trials Market Size to Increase USD 153.59 Billion by 2033
4/9/2024
According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.
-
Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging
4/9/2024
Q Bio Inc. announced the launch of Tensor Field Mapping, a new technology for Magnetic Resonance Imaging that provides detailed insights into the human body that were previously unimaginable.
-
Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
4/8/2024
Data4Cure, a leading biomedical data-to-knowledge company, today announced a late-breaking research poster presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5 to April 10, 2024, in San Diego, California.
-
Quanta Presents Preclinical Data for QTX3544, a Potent and Selective G12V-preferring Multi-KRAS Inhibitor, in Late-Breaking Session at Annual AACR Meeting 2024
4/8/2024
Quanta Therapeutics announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), in a late-breaking poster presentation session at the American Association of Cancer Research (AACR) Annual Meeting.
-
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
4/5/2024
Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.
-
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
4/5/2024
Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
-
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
4/5/2024
Predicine, Inc. A leading precision oncology company, announced that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.
-
Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays
4/4/2024
Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.
-
Rancho Biosciences Joins Forces With Davos Alzheimer's Collaborative in Global Fight Against Alzheimer's Disease
4/2/2024
Rancho Biosciences is excited to announce its work with the Davos Alzheimer's Collaborative (DAC), a first-of-its-kind global public-private platform leading an unprecedented response to Alzheimer's disease.
-
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
4/1/2024
Turbine and Harmonic Discovery have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine's Simulated Cell™ platform.
-
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
3/28/2024
Third Harmonic Bio, Inc. announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
-
Florida Cancer Specialists & Research Institute Announces Formation of Healthcare Analytics Company
3/27/2024
Florida Cancer Specialists & Research Institute, LLC announced the formation of a new healthcare analytics subsidiary.
-
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
3/26/2024
Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.